PARSONS CAPITAL MANAGEMENT INC/RI - BIO-TECHNE CORP ownership

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 431 filers reported holding BIO-TECHNE CORP in Q4 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.

About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Quarter-by-quarter ownership
PARSONS CAPITAL MANAGEMENT INC/RI ownership history of BIO-TECHNE CORP
ValueSharesWeighting
Q3 2023$466,416
-20.0%
6,852
-4.0%
0.04%
-15.9%
Q2 2023$582,839
+10.0%
7,1400.0%0.04%
+2.3%
Q1 2023$529,717
-10.5%
7,1400.0%0.04%
-12.2%
Q4 2022$591,763
+16.7%
7,140
+300.0%
0.05%
+6.5%
Q3 2022$507,000
-18.1%
1,7850.0%0.05%
-17.9%
Q2 2022$619,000
-21.4%
1,785
-1.9%
0.06%
-6.7%
Q1 2022$788,000
-16.3%
1,8190.0%0.06%
-10.4%
Q4 2021$941,000
+6.8%
1,8190.0%0.07%
-2.9%
Q3 2021$881,000
+7.6%
1,8190.0%0.07%
+9.5%
Q2 2021$819,000
+17.8%
1,8190.0%0.06%
+10.5%
Q1 2021$695,000
+20.2%
1,8190.0%0.06%
+14.0%
Q4 2020$578,000
+28.2%
1,8190.0%0.05%
+13.6%
Q3 2020$451,000
-6.0%
1,8190.0%0.04%
-13.7%
Q2 2020$480,000
+96.7%
1,819
+41.4%
0.05%
+64.5%
Q1 2020$244,000
-13.5%
1,2860.0%0.03%
+10.7%
Q4 2019$282,000
+11.9%
1,2860.0%0.03%
+3.7%
Q3 2019$252,000
-6.0%
1,2860.0%0.03%
-6.9%
Q2 2019$268,000
+5.1%
1,2860.0%0.03%
+3.6%
Q1 2019$255,000
-2.7%
1,2860.0%0.03%0.0%
Q3 2018$262,000
+118.3%
1,286
+7.2%
0.03%
+64.7%
Q1 2015$120,0001,2000.02%
Other shareholders
BIO-TECHNE CORP shareholders Q4 2020
NameSharesValueWeighting ↓
Broadcrest Asset Management, LLC 300,000$24,489,00021.05%
Montanaro Asset Management Ltd 388,800$31,737,7445.02%
Sandhill Capital Partners LLC 502,447$41,014,7753.74%
Brown Capital Management 3,160,892$258,023,6143.66%
DF DENT & CO INC 3,275,617$267,388,6403.62%
Ownership Capital B.V. 2,282,104$186,288,1503.26%
Jackson Square Partners, LLC 1,361,789$111,162,8363.24%
STONE RUN CAPITAL, LLC 88,135$7,194,4603.20%
Pembroke Management, LTD 339,591$27,720,8132.99%
Summit Creek Advisors LLC 283,693$23,157,8602.90%
View complete list of BIO-TECHNE CORP shareholders